Physicians’ attitudes towards use of digital media in clinic and practice: a national NOGGO-AIO intergroup survey

Background Digitization is advancing in all areas of life, including everyday medical practice. The COVID 19 pandemic has accelerated the long-planned digitization of medicine. This survey is intended to clarify the extent to which digital media are used in patient care and to show advantages and problems.

Methods A nationwide web-based survey was conducted anonymously in 2021. The questions were designed to determine physicians' attitudes toward digital media and their use in clinical settings. Topics included were the impact of digitization on the doctor-patient relationship, the changes brought about by the COVID 19 pandemic and the potential of telemedicine.

Results A total of 289 physicians answered the survey, among them 165 gynecologists and 57 internists. 28.7% rated their institution as up-to-date regarding digitalization. Just under 25% use telemedicine for doctor-patient contact, with video consultations introduced largely as a result of the COVID 19 pandemic. 79,1% would like to see telemedicine expanded and 45.8% of all participants even assume that telemedicine will improve the doctor-patient relationship.

Conclusions Digitization in medicine has recently advanced rapidly as a result of the COVID 19 pandemic, but most physicians surveyed would like to see more digital offerings in their day-to-day work and administrative support for its implementation. Telemedicine in particular is perceived as very positive if it has already been established, but still seems to be of limited use. Further studies should also consider the patient's perspective on telemedicine.

Interessenkonflikt

Ich erkläre als korrespondierender Autor, dass ich oder einer bzw. mehrere meiner Ko-Autoren während der letzten 3 Jahre wirtschaftliche oder persönliche Verbindungen im oben genannten Sinne hatten: Interessenkonflikt Details Jalid Sehouli:- Research Funding: Roche Pharma, AstraZeneca, Bayer, Clovis, GlaxoSmith, Lilly, Tesaro-

Honorary: Tesaro, GlaxoSmith, PharmaMar, AstraZeneca, Clovis, Bayer, Roche PharmaMar, Vifor Pharma, Hexal AG, Novartis Pharma

- Consulting: Tesaro, Merck /Pfizer, PharmaMar, Clovis Oncology, AstraZeneca, Roche Pharma; GlaxoSmith, MSD, Eisai, Novocure, Oncoinvent

Klaus Pietzner:

- Honoraria/Expenses: AstraZeneca, Novartis, Roche, Tesaro/GSK, MSD Sharp & Dome

- Consulting/ Advisory Board: AstraZeneca, Roche, Tesaro/GSK, MSD Sharp & Dome

Hartmut Link

Financial interests:

- Apogepha, Advisory Board, Personal

-G1 Therapeutics, Advisory Board, Personal

- Hogg Robinson Germany, Advisory Board, Personal

- Pharmacosmos, Advisory Board, Personal

- Samsung Bioepis, Expert Testimony, Personal

- Servier Deutschland GmbH, Advisory Board, Personal

- SIGAL SMS GmbH, Advisory Board, Personal

- Takeda, Advisory Board, Personal

- Teva, Advisory Board, Personal

- Teva, Invited Speaker, Personal

- Vision Plus Mailand, Invited Speaker, Personal

- Onkodin GmbH, Ownership Interest, Personal, onkopti.de

- Viatris, Licencing Fees, Institutional, Onkodin GmbH, onchemo.com

- AMGEN, Research Grant, Institutional, No financial interest, Study with German Cancer Society

- MMF GmbH, Coordinating PI, Personal, Financial interest

- Pharmacosmos, Research Grant, Institutional, No financial interest, Grant to German Cancer Society

- Teva - Xcenda, Steering Committee Member, Personal, Financial interest

Non-financial interests: Onkodin GmbH, Project Lead, digitized oncological treatment protocols - onkopti.de, onchemo.com

Other: Ethics Committee at the Rhineland-Palatinate Medical Association,

Mainz, Other, Expert Testimony

Marlene Kranawetter:

Travel/Accomodation/Expenses: PharmaMar

Donata Grimm-Glang

Honoraria (self): Roche, ESOP, Genomic Health, Oncdyo (not in relation to this study)

Honoraria (institutional): Greiner Bio-One, VKE

Publication History

Article published online:
11 October 2022